In addition to MYC protein stabilization via ERK1/2 phosphorylation [69–71] under normal conditions, or through ERK5 when cancer cells are treated with MEK1/2 or ERK1/2 inhibitors [72, 73], our data provides a new mechanism for MYC protein regulation by KRAS oncogene. This evidence concerns the gene MAPK3 and cancer.